AbbVie Inc. Vice President-Therapeutic Areas & International Development Shao-Lee Lin oversees research and development across many diseases, but she notes that immunology is and will continue to be an important segment for the company long after Humira (adalimumab) goes off patent.
Scrip spoke with Lin during the recent American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) annual meeting in San Diego about the company's immunology R&D pipeline, including the Janus kinase (JAK) inhibitor upadacitinib and the interleukin-23 (IL-23) inhibitor risankizumab, which could help AbbVie make up for a potential multibillion-dollar revenue decline once biosimilars for the tumor necrosis factor (TNF) inhibitor Humira hit the US market in the next six years